MedPath

Cost-effectiveness study on the Provox®2 and the Groningen Ultra Low Resistance tracheoesophageal shunt prostheses.

Recruiting
Registration Number
NL-OMON22831
Lead Sponsor
Dr. B.F.A.M. van der LaanHead of department of Ear, Nose and Throat medicine University Medical Centre Groningen
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

Patients from our outpatient clinic (ENT, UMCG): post-laryngectomees that use a TE shunt prosthesis for their phonation.

Exclusion Criteria

1. Patients younger than 45 or older than 70.

2. Patients that have a metastasis or recurrence of their previous larynx carcinoma.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ifetime of both types of TE shunt prosthesis
Secondary Outcome Measures
NameTimeMethod
1. Total costs for the use of both the Provox®2 and Groningen ULR TE shunt prostheses. An incremental cost analysis.<br /><br>2. Quality of life<br /><br>3. Evaluation of both types of prostheses<br /><br>4. Preference of patients for one of both types of prostheses.<br /><br>5. Experience with replacement and -technique.<br /><br>6. Diet. Food products that influence lifetime of the TE shunt prosthesis<br /><br>7. Expenses made by patient.<br />
© Copyright 2025. All Rights Reserved by MedPath